FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082385748> ?p ?o ?g. }

• W2082385748 endingPage "2787" @default.
• W2082385748 startingPage "2780" @default.
• W2082385748 abstract "Background Intravenous nicardipine is commonly used to reduce elevated blood pressure in acute intracerebral hemorrhage (ICH). We determined factors associated with nicardipine dosing and the association of dose with clinical outcomes in hyperacute ICH. Methods Hyperacute (<3 hours from onset) ICH patients with initial systolic blood pressure (SBP) greater than 180 mm Hg were included. All patients initially received 5 mg/hour of intravenous nicardipine. The dose was adjusted to maintain SBP between 120 and 160 mm Hg. Associations of maximum hourly and total doses with early neurologic deterioration (END), hematoma expansion (>33%), and modified Rankin Scale score 4-6 at 3 months were assessed. Results Two hundred six patients (81 women, 65.8 ± 11.8 years) were studied. Initial SBP was 201.9 ± 15.9 mm Hg. Maximum and total nicardipine doses were 9.1 ± 4.2 mg/hour and 123.7 ± 100.2 mg/day, respectively. Multivariate analyses revealed that men (standardized regression coefficient [β] = .20, P = .0030 for maximum dose; β = .25, P = .0002 for total dose), age (β = −.28, P = .0002; β = −.25, P = .0005), and initial SBP (β = .19, P = .0018; β = .18, P = .0021) were independently associated with both maximum and total doses. Body weight (β = .20, P = .0084) was independently associated with total dose. After multivariate adjustment, maximum dose (per 1 mg/hour; odds ratio [OR], 1.25; 95% confidence interval [CI], 1.09-1.45) was independently, and total dose (per 10 mg/day; OR, 1.06; 95% CI, .998-1.132) tended to be independently, associated with END. Nicardipine dose was not associated with hematoma expansion or 3-month outcome. Conclusions Nicardipine dose is roughly predictable with sex, age, body weight, and initial SBP in acute ICH. The maximum dose was associated with neurologic deterioration. Intravenous nicardipine is commonly used to reduce elevated blood pressure in acute intracerebral hemorrhage (ICH). We determined factors associated with nicardipine dosing and the association of dose with clinical outcomes in hyperacute ICH. Hyperacute (<3 hours from onset) ICH patients with initial systolic blood pressure (SBP) greater than 180 mm Hg were included. All patients initially received 5 mg/hour of intravenous nicardipine. The dose was adjusted to maintain SBP between 120 and 160 mm Hg. Associations of maximum hourly and total doses with early neurologic deterioration (END), hematoma expansion (>33%), and modified Rankin Scale score 4-6 at 3 months were assessed. Two hundred six patients (81 women, 65.8 ± 11.8 years) were studied. Initial SBP was 201.9 ± 15.9 mm Hg. Maximum and total nicardipine doses were 9.1 ± 4.2 mg/hour and 123.7 ± 100.2 mg/day, respectively. Multivariate analyses revealed that men (standardized regression coefficient [β] = .20, P = .0030 for maximum dose; β = .25, P = .0002 for total dose), age (β = −.28, P = .0002; β = −.25, P = .0005), and initial SBP (β = .19, P = .0018; β = .18, P = .0021) were independently associated with both maximum and total doses. Body weight (β = .20, P = .0084) was independently associated with total dose. After multivariate adjustment, maximum dose (per 1 mg/hour; odds ratio [OR], 1.25; 95% confidence interval [CI], 1.09-1.45) was independently, and total dose (per 10 mg/day; OR, 1.06; 95% CI, .998-1.132) tended to be independently, associated with END. Nicardipine dose was not associated with hematoma expansion or 3-month outcome. Nicardipine dose is roughly predictable with sex, age, body weight, and initial SBP in acute ICH. The maximum dose was associated with neurologic deterioration." @default.
• W2082385748 created "2016-06-24" @default.
• W2082385748 creator A5008694263 @default.
• W2082385748 creator A5011996744 @default.
• W2082385748 creator A5017338106 @default.
• W2082385748 creator A5017863780 @default.
• W2082385748 creator A5018515174 @default.
• W2082385748 creator A5028025164 @default.
• W2082385748 creator A5029421463 @default.
• W2082385748 creator A5035717519 @default.
• W2082385748 creator A5042534277 @default.
• W2082385748 creator A5055860707 @default.
• W2082385748 creator A5056591092 @default.
• W2082385748 creator A5058735880 @default.
• W2082385748 creator A5059013510 @default.
• W2082385748 creator A5064012927 @default.
• W2082385748 creator A5076132169 @default.
• W2082385748 creator A5080104670 @default.
• W2082385748 creator A5081212360 @default.
• W2082385748 creator A5087442638 @default.
• W2082385748 date "2014-11-01" @default.
• W2082385748 modified "2023-10-08" @default.
• W2082385748 title "Intravenous Nicardipine Dosing for Blood Pressure Lowering in Acute Intracerebral Hemorrhage: The Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage Study" @default.
• W2082385748 cites W151371462 @default.
• W2082385748 cites W1556631311 @default.
• W2082385748 cites W1965518725 @default.
• W2082385748 cites W1987519248 @default.
• W2082385748 cites W1988880179 @default.
• W2082385748 cites W1997695960 @default.
• W2082385748 cites W2008889136 @default.
• W2082385748 cites W2024230525 @default.
• W2082385748 cites W2038997428 @default.
• W2082385748 cites W2040736023 @default.
• W2082385748 cites W2056856602 @default.
• W2082385748 cites W2070501236 @default.
• W2082385748 cites W2082749557 @default.
• W2082385748 cites W2103369491 @default.
• W2082385748 cites W2112040973 @default.
• W2082385748 cites W2114214167 @default.
• W2082385748 cites W2138238488 @default.
• W2082385748 cites W2139856993 @default.
• W2082385748 cites W2172222894 @default.
• W2082385748 cites W2316878969 @default.
• W2082385748 cites W2548934243 @default.
• W2082385748 cites W2561826548 @default.
• W2082385748 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.029" @default.
• W2082385748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25314943" @default.
• W2082385748 hasPublicationYear "2014" @default.
• W2082385748 type Work @default.
• W2082385748 sameAs 2082385748 @default.
• W2082385748 citedByCount "10" @default.
• W2082385748 countsByYear W20823857482015 @default.
• W2082385748 countsByYear W20823857482016 @default.
• W2082385748 countsByYear W20823857482018 @default.
• W2082385748 countsByYear W20823857482019 @default.
• W2082385748 countsByYear W20823857482022 @default.
• W2082385748 countsByYear W20823857482023 @default.
• W2082385748 crossrefType "journal-article" @default.
• W2082385748 hasAuthorship W2082385748A5008694263 @default.
• W2082385748 hasAuthorship W2082385748A5011996744 @default.
• W2082385748 hasAuthorship W2082385748A5017338106 @default.
• W2082385748 hasAuthorship W2082385748A5017863780 @default.
• W2082385748 hasAuthorship W2082385748A5018515174 @default.
• W2082385748 hasAuthorship W2082385748A5028025164 @default.
• W2082385748 hasAuthorship W2082385748A5029421463 @default.
• W2082385748 hasAuthorship W2082385748A5035717519 @default.
• W2082385748 hasAuthorship W2082385748A5042534277 @default.
• W2082385748 hasAuthorship W2082385748A5055860707 @default.
• W2082385748 hasAuthorship W2082385748A5056591092 @default.
• W2082385748 hasAuthorship W2082385748A5058735880 @default.
• W2082385748 hasAuthorship W2082385748A5059013510 @default.
• W2082385748 hasAuthorship W2082385748A5064012927 @default.
• W2082385748 hasAuthorship W2082385748A5076132169 @default.
• W2082385748 hasAuthorship W2082385748A5080104670 @default.
• W2082385748 hasAuthorship W2082385748A5081212360 @default.
• W2082385748 hasAuthorship W2082385748A5087442638 @default.
• W2082385748 hasConcept C126322002 @default.
• W2082385748 hasConcept C127413603 @default.
• W2082385748 hasConcept C156957248 @default.
• W2082385748 hasConcept C17624336 @default.
• W2082385748 hasConcept C2777094939 @default.
• W2082385748 hasConcept C2777288759 @default.
• W2082385748 hasConcept C2778043224 @default.
• W2082385748 hasConcept C2780645631 @default.
• W2082385748 hasConcept C2780931571 @default.
• W2082385748 hasConcept C3020199598 @default.
• W2082385748 hasConcept C42219234 @default.
• W2082385748 hasConcept C44249647 @default.
• W2082385748 hasConcept C541997718 @default.
• W2082385748 hasConcept C71924100 @default.
• W2082385748 hasConcept C78519656 @default.
• W2082385748 hasConcept C84393581 @default.
• W2082385748 hasConceptScore W2082385748C126322002 @default.
• W2082385748 hasConceptScore W2082385748C127413603 @default.
• W2082385748 hasConceptScore W2082385748C156957248 @default.
• W2082385748 hasConceptScore W2082385748C17624336 @default.
• W2082385748 hasConceptScore W2082385748C2777094939 @default.
• W2082385748 hasConceptScore W2082385748C2777288759 @default.

• next